Search: onr:"swepub:oai:DiVA.org:liu-106025" >
Impact of in vivo T...
-
Baron, F.University of Liege, Belgium
(author)
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor : a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
- Article/chapterEnglish2014
Publisher, publication year, extent ...
-
2014-01-13
-
Nature Publishing Group,2014
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-106025
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-106025URI
-
https://doi.org/10.1038/bmt.2013.204DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
The impact of in vivo T-cell depletion on transplantation outcomes in patients transplanted with reduced-intensity conditioning (RIC) remains controversial. This study assessed the outcome of 1250 adult patients with de novo AML in first CR (CR1) given PBSC from HLA-identical siblings after chemotherapy-based RIC. A total of 554 patients did not receive any form of in vivo T-cell depletion (control group), whereas antithymocyte globulin (ATG) and alemtuzumab were given in 444 and 252 patients, respectively. The incidences of grade II-IV acute GVHD were 21.4, 17.6 and 10.2% in control, ATG and alemtuzumab patients, respectively (P less than 0.001). In multivariate analysis, the use of ATG and the use of alemtuzumab were each associated with a lower risk of chronic GVHD (P less than 0.001 each), but a similar risk of relapse, and of nonrelapse mortality, and similar leukemia-free survival and OS. Further, among patients given BU-based RIC, the use of less than 6 mg/kg ATG did not increase the risk of relapse (hazard ratio, HR=1.1), whereas there was a suggestion for higher relapse risk in patients given greater than= 6 mg/kg ATG (HR=1.4, P=0.08). In summary, these data suggest that a certain amount of in vivo T-Cell depletion can be safely used in the conditioning of AML patients in CR1 given PBSC after chemotherapy-based RIC.
Subject headings and genre
-
reduced-intensity conditioning; AML; GVHD; ATG; alemtuzumab
Added entries (persons, corporate bodies, meetings, titles ...)
-
Labopin, M.Hospital Saint Antoine / Pierre-and-Marie-Curie University, Paris, France
(author)
-
Blaise, D.CHU Marseille, France
(author)
-
Lopez-Corral, L.Hospital Clinico Universitario, Salamanca, Spain
(author)
-
Vigouroux, S.CHU Bordeaux, France
(author)
-
Craddock, C.Queen Elizabeth Hospital and School of Cancer Studies, University of Birmingham, UK
(author)
-
Attal, M.CHU Toulouse, France
(author)
-
Jindra, P.Charles University Medical School and Teaching Hospital, Pilsen, Czech Republic
(author)
-
Goker, H.Hacettepe University, Ankara,Turkey
(author)
-
Socie, G.Saint-Louis Hospital, Paris, France
(author)
-
Chevallier, P.CHU Nantes, France
(author)
-
Browne, P.St James Hospital, Dublin, Ireland
(author)
-
Sandstedt, A.Östergötlands Läns Landsting,Hematologiska kliniken US
(author)
-
Duarte, R. F.Hospital Llobregat, Barcelona, Spain
(author)
-
Nagler, A.Tel Aviv University, Israel
(author)
-
Mohty, M.Hospital Saint Antoine / Pierre-and-Marie-Curie University, Paris, France
(author)
-
University of Liege, BelgiumHospital Saint Antoine / Pierre-and-Marie-Curie University, Paris, France
(creator_code:org_t)
Related titles
-
In:Bone Marrow Transplantation: Nature Publishing Group49:3, s. 389-3960268-33691476-5365
Internet link
Find in a library
To the university's database
- By the author/editor
-
Baron, F.
-
Labopin, M.
-
Blaise, D.
-
Lopez-Corral, L.
-
Vigouroux, S.
-
Craddock, C.
-
show more...
-
Attal, M.
-
Jindra, P.
-
Goker, H.
-
Socie, G.
-
Chevallier, P.
-
Browne, P.
-
Sandstedt, A.
-
Duarte, R. F.
-
Nagler, A.
-
Mohty, M.
-
show less...
- Articles in the publication
-
Bone Marrow Tran ...
- By the university
-
Linköping University